Pharma Q3 Results Preview: Merck & Co., Merck KGaA
Executive Summary
Investors will be eager to hear updates on Merck & Co.'s Keytruda market share versus other PD-1/L1 competitors in lung cancer, as well as other indications; Merck KGaA followers are watching for what sort of start its Pfizer Inc.-partnered checkpoint inhibitor Bavencio and the new multiple sclerosis drug Mavenclad have got off to.
You may also be interested in...
Merck Calls It Quits On Anacetrapib
Despite the success in the REVEAL outcomes trial for the cholesteryl ester transfer protein (CETP) inhibitor, Merck will not submit the cholesterol therapy for regulatory approval.
No More Nucs: Merck & Co. Cedes HCV Market To Gilead, AbbVie
Pharma ends HCV development, pulling plug on next-generation two-drug and three-drug combos for hepatitis C and rendering the $3.9bn buyout of Idenix in 2014 a failed gambit.
Merck KGaA/Pfizer Get Europe OK For Bavencio In Rare Skin Cancer
The Merkel cell carcinoma area is very niche but getting approval means that Merck and Pfizer can now prepare to compete with the likes of Opdivo and Keytruda in the European PD-1/PD-L1 space.